BACKGROUND. The objective of this study was to determine the impact of malignant
|
|
- Myra Long
- 5 years ago
- Views:
Transcription
1 1397 The Clinical Significance of Malignant Pleural Effusions in Patients with Optimally Debulked Ovarian Carcinoma Ram Eitan, M.D. Douglas A. Levine, M.D. Nadeem Abu-Rustum, M.D. Yukio Sonoda, M.D. Jae N. Huh, B.A. Corinna C. Franklin, B.A. Tobey A. Stevens, M.D. Richard R. Barakat, M.D. Dennis S. Chi, M.D. Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York. BACKGROUND. The objective of this study was to determine the impact of malignant pleural effusions on survival in patients with optimally debulked, advanced epithelial ovarian carcinoma. METHODS. The authors conducted a retrospective review of all patients with advanced epithelial ovarian carcinoma who underwent optimal primary cytoreduction at their institution between January 1987 and August Survival rates were compared between pts with optimally debulked Stage IIIC epithelial ovarian carcinoma and patients with optimally debulked Stage IV epithelial ovarian carcinoma (according to the International Federation of Gynecology and Obstetrics [FIGO] staging system) based on cytology-proven malignant pleural effusions. RESULTS. Ninety-nine patients were identified, and 97 of those patients were evaluable. The group with Stage IIIC disease included 76 patients, and the group with Stage IV disease included 21 patients. The median age at diagnosis was 55 years (range, years). The majority of patients received platinum-based chemotherapy after undergoing optimal primary cytoreduction. Age, tumor grade and histology, and the percentage of patients with ascites were similar in the two groups. The median survival rate was 58 months for patients who had Stage IIIC disease and 30 months for patients who had Stage IV disease (P 0.016). CONCLUSIONS. Although both groups underwent optimal cytoreduction in the abdomen/pelvis and were treated in a similar fashion, the median survival rate of patients with malignant pleural effusions was significantly shorter than the survival of patients without effusions. Many factors that led to or were manifested by pleural effusions, such as undetected bulky residual intrathoracic disease, may have been the cause for this survival difference. In the patients with effusions, one or more of these contributing factors may have led to the observed decreased survival rate, warranting further investigation. Cancer 2005;103: American Cancer Society. KEYWORDS: ovarian carcinoma, pleural effusion, survival, optimal debulking. Address for reprints: Dennis S. Chi, M.D., Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, MRI-1026, New York, NY 10021; Fax: (212) ; gynbreast@mskcc.org Received July 21, 2004; revision received December 3, 2004; accepted December 3, The majority of women who develop epithelial ovarian carcinoma will present with advanced Stage III or IV disease. 1 Stage III disease has been defined by the International Federation of Gynecology and Obstetrics (FIGO) as histologically proven, microscopic, extrapelvic spread (Stage IIIA); extrapelvic disease measuring 2 cm (Stage IIIB); and extrapelvic disease measuring 2 cm in size or positive retroperitoneal or inguinal lymph nodes (Stage IIIC). Stage IV disease has been defined as parenchymal liver metastasis, malignant pleural effusion, or other distant extraabdominal sites of disease. No substaging has been set for Stage IV in the FIGO staging system. In the 1998 FIGO annual report concerning the results of treat American Cancer Society DOI /cncr Published online 22 February 2005 in Wiley InterScience (
2 1398 CANCER April 1, 2005 / Volume 103 / Number 7 ment in gynecologic malignancies, 2 among nearly 3000 patients with ovarian carcinoma who were diagnosed between 1990 and 1992, it was shown that patients who had Stage IV disease fare much worse (11% survival) compared with patients who had Stage III disease (25% survival). This also was demonstrated by Heintz et al., 3 who reported that Stage IV confers a worse survival than Stage III disease (17% vs % 5-year survival, respectively). In those reports, no differentiation was made between patients diagnosed with Stage IV disease based on malignant pleural effusion and those with parenchymal liver, lung, or other extraperitoneal spread. The few reports on the survival in the subclasses of patients with Stage IV disease reported conflicting results, with some reporting a better prognosis for patients with pleural effusions, 4 and some reporting no difference in survival. 5 Over the past 3 decades, it has been established that 1 of the most important prognostic factors in patients with advanced epithelial ovarian carcinoma is optimal abdominal cytoreduction at initial surgery. 6 8 This benefit also has been shown for patients with Stage IV epithelial ovarian carcinoma, 9 13 although, in these patients, disease has spread to sites outside the abdomen. Patients with a malignant pleural effusion at the time of diagnosis but with no evidence of bulky disease outside the abdomen usually undergo surgery with the intent of optimal abdominopelvic debulking. The pleural effusion, although it upstages the patient, is considered to be similar to ascites and usually will not deter the surgeon from proceeding with planned abdominal cytoreduction. It is believed that this patient subpopulation may benefit from cytoreduction, similar to patients with bulky abdominal disease and ascites but without pleural effusion. However, it must be determined whether the malignant pleural effusion is a sign of bulkier, pleural-based disease or of extraabdominal disease that is not detected otherwise. Although historically it was considered part of the Stage IV category in the FIGO staging system, it is not clear whether the prognosis for patients with malignant pleural effusion differs from the prognosis for patients with Stage IIIC disease. The objective of the current study was to test the hypothesis that patients with Stage IV (due to malignant pleural effusion) optimally debulked epithelial ovarian carcinoma only will have survival similar to the survival of patients with optimally debulked Stage III epithelial ovarian carcinoma. MATERIALS AND METHODS After obtaining Institutional Review Board approval, we used the Virginia K. Pierce Gynecology Service prospectively acquired data base to identify all patients diagnosed with Stage IIIC epithelial ovarian carcinoma and Stage IV epithelial ovarian carcinoma based on cytology-proven, malignant pleural effusions only who underwent primary optimal cytoreductive surgery at our institution between January 1987 and August We performed a retrospective chart review and collected all demographic, clinical, surgical, and pathologic information. Patients with Stage IV epithelial ovarian carcinoma not due to malignant pleural effusions alone and patients with epithelial ovarian carcinoma of low-malignant potential were excluded from the analysis. All patients were staged according to the criteria set by FIGO. 14 Overall survival and progression-free survival were calculated from the date of initial surgery to death or diagnosis of recurrent epithelial ovarian carcinoma, respectively, or to the date of the last follow-up visit for those patients who were still alive. A standard censoring technique was used. Optimal cytoreduction was defined as surgery that left residual disease measuring 1 cm in greatest dimension. Standard two-sided statistical tests were used to compare clinical characteristics between the two groups. Survival was calculated using the Kaplan Meier method, and differences in survival were compared using the log-rank test. RESULTS In total, 99 patients were identified within the study period, and 97 of those patients were evaluable. Seventy-six patients had Stage IIIC disease based on upper abdominal disease that measured 2 cm and comprised the Stage IIIC patient group. The 21 patients who had Stage IV disease based on cytologically confirmed, malignant pleural effusions comprised the Stage IV patient group. All patients underwent a laparotomy with optimal debulking of their tumor to 1 cm of residual disease. Patient characteristics are presented in Table 1. No difference was found in patient age, tumor grade, tumor histology, or percentage of patients with ascites between the two groups. Serous histology was found in 55% and 62% of patients with Stage IIIC and Stage IV disease, respectively. Architecture Grade 3 tumors were found in 58% of patients with Stage IIIC disease and in 62% of patients with Stage IV disease. The majority of patients in both groups received platinumbased chemotherapy after surgical debulking (in combination with paclitaxel, cyclophosphamide, or alone). Most patients received a full course of platinum-based chemotherapy ( 6 cycles), including 62 patients in the Stage IIIC group (82%) and 16 patients in the Stage IV group (80%).
3 Pleural Effusion in Ovarian Ca/Eitan et al TABLE 1 Patient Characteristics a Characteristic Group 1: Stage IIIC b (n 76 patients) No. of patients (%) Group 2: Stage IV (n 21 patients) Age (yrs) Median Range Histology Serous 42 (55) 13 (62) Mucinous 2 (3) 1 (5) Endometrioid 17 (22) 6 (28) Clear cell 6 (8) 0 (0) Mixed 4 (5) 1 (5) Other 5 (6) 0 (0) Grade 1 4 (5) 2 (9) 2 24 (32) 6 (29) 3 44 (58) 13 (62) Unknown 4 (5) 0 (0) Ascites Yes 59 (78) 19 (91) No 9 (12) 2 (9) Unknown 8 (10) 0 (0) CA 125 (units/ml) Median Range 30 10, ,600 Primary chemotherapy Platinum-based 68 (89) 20 (95) cyclophosphamide alone 3 (4) 1 (5) No chemotherapy 2 (3) 0 (0) Unknown 3 (4) 0 (0) a P values were not statistically significant. b Staging was performed according to the International Federation of Gynecology and Obstetrics (FIGO). TABLE 2 Recurrence Patterns in Optimally Debulked Patients with Stage IIIC and IV Epithelial Ovarian Carcinoma Variable Stage IIIC a (n 76 patients) Stage IV (n 21 patients) P value No. of patients who presented with recurrent epithelial ovarian carcinoma 53 (70%) 15 (71%) NS Time to recurrence (mos) Mean SD % CI NS: not significant; SD: standard deviation; 95% CI: 95% confidence interval. a Staging was performed according to the International Federation of Gynecology and Obstetrics (FIGO). When they were evaluated at the end of primary chemotherapy, 57% of patients in each group were assessed clinically with no evidence of disease (NED) (negative scans, normal CA 125 levels). One patient in each group had residual disease in the chest found at this point (5% of patients in the Stage IV group who were not assessed with NED and 3% of patients in the Stage IIIC group). Eight patients in the Stage IV group and 52 patients in the Stage IIIC group underwent second-look surgery at the end of primary chemotherapy (38% and 67%, respectively). Surprisingly, only 1 patient in the Stage IV group, compared with 20 patients in the Stage IIIC group, were identified as negative for disease at second-look surgery (12% and 38%, respectively). The median CA 125 levels at the time patients were diagnosed with epithelial ovarian carcinoma were higher in the Stage IIIC group compared with the Stage IV group, with a wide range of results but without a statistically significant difference noted between the groups (P 0.59) (Table 1). The median follow-up was 48 months for patients with Stage IIIC disease and 35 months for patients with Stage IV disease. Table 2 describes disease recurrence patterns in both groups. Patients in both groups had the same likelihood of overall recurrence, although recurrences in patients with Stage IV disease developed significantly earlier compared with recurrences in patients with Stage IIIC disease (12 months vs. 21 months, respectively; P 0.04). This difference in progression-free survival also is demonstrated graphically in Figure 1. Three patients in each group were identified with disease in the chest as the first site of recurrence (14% of patients in the Stage IV group and 5% of patients in the Stage IIIC group; P 0.15). In addition, 47% of patients in the Stage IV group developed recurrences in the abdomen, compared with 65% of patients in the Stage IIIC group (P 0.25). Overall survival is demonstrated in Figure 2. The median overall survival was 58 months for the Stage IIIC group compared with 30 months for the Stage IV group based on malignant pleural effusions (P 0.016) (Fig. 2). DISCUSSION Cytoreductive surgery followed by platinum-based chemotherapy has become the standard of care for advanced-stage epithelial ovarian carcinoma. 15 All patients diagnosed with what appears to be resectable disease undergo surgery with the intent of performing optimal abdominopelvic cytoreductive surgery. We believe that a maximal surgical effort should be employed, and we recently reported a statistically significant increase in optimal debulking rates at our institution by incorporating extensive upper abdominal procedures into our surgical approach. 16
4 1400 CANCER April 1, 2005 / Volume 103 / Number 7 FIGURE 1. Progression-free survival for patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC versus Stage IV, optimally debulked epithelial ovarian carcinoma. FIGURE 2. Overall survival for patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC versus Stage IV, optimally debulked epithelial ovarian carcinoma. Malignant pleural effusion in a patient diagnosed with epithelial ovarian carcinoma confers Stage IV disease but does not preclude optimal debulking Our data show that patients with optimally debulked, Stage IV disease based on malignant pleural effusions have a shorter time to recurrence and decreased overall survival compared with optimally debulked patients who have Stage IIIC disease. The main factor that leads to the poorer prognosis for patients with pleural effusions is not known. Are the tumors presenting with pleural effusion inherently more aggressive? Do these tumors present enhanced resistance to chemotherapy? Are more invasive genes being overexpressed in these patients? Microarray studies performed at our institution and others comparing tissue from patients with Stage III and Stage IV epithelial ovarian carcinoma hopefully will answer some of these questions. However, those studies may find that there is no difference in gene expression between these groups and the biology of their tumors is similar. Other factors to consider are surgeon bias when confronting a patient with disease that already has spread outside the abdomen. Is the surgical effort similar in both groups? Because the optimal debulking parameters are the only tool we currently have to assess for residual disease after surgical debulking procedures for epithelial ovarian carcinoma, this bias hopefully was eliminated from the current study, in which all patients underwent optimal debulking at the same institution. With that in mind, it is clear that more patients in the Stage IIIC group were offered second-look surgery (67% vs. 38%). It also is possible to speculate that some patients with malignant pleural effusions may have harbored bulky (suboptimal), pleural-based disease that was not diagnosed radiographically. Only two patients in the Stage IV group and no patients in the Stage IIIC group underwent computed tomography (CT) scans of the chest before surgery. Pleural effusions were diagnosed using plain chest X-rays only. Therefore, we cannot comment on the value of chest CT scanning before surgery in patients with Stage IV disease, although we now perform chest CT scans on all patients with epithelial ovarian carcinoma at the time of diagnosis. In patients with malignant pleural effusions, the benefits of optimal abdominopelvic cytoreduction may be blunted or negated altogether due to undiagnosed intrathoracic disease. Fifty-seven percent of patients were classified clinically with NED at the end of primary treatment, although it was found that more patients in the Stage IV group harbored disease when they underwent thorough second-look surgery. The question of increased tumor resistance to cytotoxic agents is raised again. No difference was found in the rates of chest residual disease at the completion of chemotherapy, nor was any difference found in the rates of first recurrence in the chest between the two groups. Again, it appears likely that the malignant pleural effusion is a sign of a more aggressive tumor. We recently reported our experience with the performance of video-assisted thoracoscopic surgery (VATS) prior to abdominal exploration in 12 patients with suspected advanced-stage ovarian carcinoma and moderate-to-large pleural effusions. 17 In 50% of those patients, solid pleural-based tumor was identified that was not observed previously on diagnostic imaging studies, and in 25% of patients, the tumor nodules measured 1 cm in greatest dimension. Moreover, on final analysis, six of those patients had advanced ovarian or fallopian tube carcinoma and
5 Pleural Effusion in Ovarian Ca/Eitan et al malignant pleural effusions. In 5 of those 6 patients (83%), solid tumor was discovered at VATS and in 3 patients (50%), a tumor measuring 1 cm was identified. Therefore, it is our impression that patients with moderate-to-large pleural effusions may benefit from a VATS procedure prior to abdominal exploration. If solid tumor measuring 1 cm is detected at the time of VATS, then an option of intrathoracic cytoreduction, as described by Eisenkop, 18 could be considered. To our knowledge, although neoadjuvant chemotherapy has been discussed in the literature extensively, the indications for its use in patients with epithelial ovarian carcinoma still are not clear. If the reason for decreased survival in patients with Stage IV disease is a decreased sensitivity to cytotoxic agents, then will neoadjuvant treatment be of benefit in this group? This question remains to be answered; however, we believe that the small benefit offered to these patients by surgery is a factor toward considering them for neoadjuvant chemotherapy In the current retrospective cohort study, the survival of optimally cytoreduced patients with malignant pleural effusions was significantly shorter compared with the survival of patients with Stage IIIC, optimally cytoreduced disease without effusions. Selection bias and other confounders found in retrospective studies also were possibilities in this study, and we made efforts to minimize them as much as possible. Prospective data regarding this issue currently are lacking, and the current study provided further evidence to support the current FIGO staging system in which patients who have pleural effusions are upstaged and are expected to have a worse prognosis compared with patients who do not have extraperitoneal disease. The question of whether Stage IV disease should be subdivided based on sites of extraperitoneal spread remains open. The cause for this survival difference currently is not known and regardless of whether it is more aggressive disease or undetected intrathoracic disease in the patients with effusions, methods such as VATS to detect occult disease in this patient population should be considered to delineate the extent of disease better prior to the initiation of therapy; this is an area of ongoing investigation. REFERENCES 1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, CA Cancer J Clin. 2004;54: [No authors listed.] FIGO annual report on the results of treatment in gynecologic cancer. J Epidemiol Biostat. 1998; 3: Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat. 2001;6: Penson RT, Skates SJ, Fuller AJ Jr., Seiden MV. Clinical course of Stage IV epithelial ovarian cancer. J Clin Oncol. 1999;17: Bonnefoi H, A Hern RP, Fisher C, et al. Natural history of Stage IV epithelial ovarian cancer. J Clin Oncol. 1999;17: Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery [review]. Gynecol Oncol. 1994;55(3 Pt 2):S91 S Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20: Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol. 2001;82: Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol. 1997;64: Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC. Effect of surgical debulking on survival in Stage IV ovarian cancer. Gynecol Oncol. 1997;64: Munkarah AR, Hallum AV III, Morris M, et al. Prognostic significance of residual disease in patients with Stage IV epithelial ovarian cancer. Gynecol Oncol. 1997;64: Bristow RE, Montz F, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in Stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72: Naik R, Nordin A, Cross PA, Hemming D, de Barros Lopes A, Monaghan JM. Optimal cytoreductive surgery is an independent prognostic indicator in Stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol. 2000;78: International Federation of Gynecology and Obstetrics (FIGO) Cancer Committee. Staging announcement. Gynecol Oncol. 1986;25: Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol. 2000;19: Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for Stage IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal carcinoma: a change in surgical approach. Gynecol Oncol. 2004;94: Chi DS, Abu-Rustum NR, Sonoda Y, et al. The benefit of video-assisted thoracoscopic surgery (VATS) prior to planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol Oncol. 2004;94: Eisenkop SM. Thoracoscopy for the management of advanced epithelial ovarian cancer a preliminary report. Gynecol Oncol. 2002;84: Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 2001;92: Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P. Neoadjuvant chemotherapy of primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71: Schwartz PE, Thomas JR, Chambers JT, Kohorn EI, Thiel RP. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol. 1999;72:93 99.
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationIntroduction. Abstract
Gynecologic Oncology 103 (2006) 1083 1090 www.elsevier.com/locate/ygyno The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC
More informationSurgical Cytoreduction in Ovarian Cancer
Review Article [1] May 01, 2004 Ovarian Cancer [2], Oncology Journal [3] By Wayne A. Mccreath, MD [4] and Dennis S. Chi, MD [5] The majority of ovarian cancer patients present with advanced-stage disease,
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 1 JANUARY 1 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer:
More informationGynecologic Oncology
Gynecologic Oncology 124 (2012) 10 14 Contents lists available at SciVerse ScienceDirect Gynecologic Oncology journal homepage: www.elsevier.com/locate/ygyno An analysis of patients with bulky advanced
More informationStage 3 ovarian cancer survival rate
Search Stage 3 ovarian cancer survival rate 19-5-2017 If you've been diagnosed with ovarian cancer, it's natural to wonder about your prognosis. Learn about survival rates, outlook, and more. Take the
More informationStage 3 ovarian cancer survival rate
Stage 3 ovarian cancer survival rate Gogamz Menu The latest ovarian cancer survival statistics for the UK for Health Professionals. See data for age, trends over time, stage at diagnosis and more. 5-8-2014
More informationCAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA?
CAN PREOPERATIVE CA-125 PREDICT RESECTABILITY OF TUMOR IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CARCINOMA? M. Modarres-Gilani *1, F. Ghaemmaghami 1, S. Ansaripoor 1, M. Shariat 2 and F. Zaeri 3 1)
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary
North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer
More informationMarcello Deraco M.D. Responsible Peritoneal Malignancies
Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey
More informationInteractive Staging Bee
Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment
More informationCytoreductive Surgery for Advanced Epithelial Tumors of the Ovary: Technical Considerations and Outcome
Journal of the Egyptian Nat. Cancer Inst., Vol., No. 3, September: -, Cytoreductive Surgery for Advanced Epithelial Tumors of the Ovary: Technical Considerations and Outcome EL-SAYED ASHRAF KHALIL, M.D.*;
More informationIn the United States, ovarian cancer is the leading
Aggressive Surgical Effort and Improved Survival in Advanced-Stage Ovarian Cancer Giovanni D. Aletti, MD, Sean C. Dowdy, MD, Bobbie S. Gostout, MD, Monica B. Jones, MD, C. Robert Stanhope, MD, Timothy
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationWomen s Imaging Original Research
Women s Imaging Original Research Lakhman et al. Postoperative CT as Prognostic Biomarker in Gynecologic Cancer Women s Imaging Original Research Yulia Lakhman 1 Oguz Akin 1 Michael J. Sohn 1 Junting Zheng
More informationDoes serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study
Guo and Peng Journal of Ovarian Research (2017) 10:14 DOI 10.1186/s13048-017-0310-y RESEARCH Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian
More informationThe role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
Radiology and Oncology Ljubljana Slovenia www.radioloncol.com research article 341 The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer Erik Škof 1, Sebastjan
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationCurrent state of upfront treatment for newly diagnosed advanced ovarian cancer
Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/24096
More informationSurvival impact of cytoreductive surgery ın advanced stage EOC
Survival impact of cytoreductive surgery ın advanced stage EOC Ayhan Ali, MD Baskent University School of Medicine Department of Obstetrics and Gynecology, Division of Gynecologic Oncology 1 OVARIAN CANCER
More informationPrediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer
Original Article J Gynecol Oncol Vol. 22, No. 4:269-274 pissn 2005-0380 eissn 2005-0399 Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian
More informationCarcinoma of the Fallopian Tube
119 Carcinoma of the Fallopian Tube APM HEINTZ, F ODICINO, P MAISONNEUVE, U BELLER, JL BENEDET, WT CREASMAN, HYS NGAN and S PECORELLI STAGING Anatomy Primary site The Fallopian tube extends from the posterior
More informationResidual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany
Residual Tumor Following Surgery: The Strongest Prognostic Factor or a Myth? Philipp Harter, MD Kliniken Essen Mitte Essen, Germany What Are Our Questions Q1: Prognostic factor residual disease? Q2: Differences
More informationSURGERY OF RECURRENCIES
La chirurgia Bergamo, delle 6 th May recidive 2011 SURGERY OF RECURRENCIES Pierluigi Benedetti Panici Calcagno Marco, Gasparri Maria Luisa, Domenici Lavinia, Bellati Filippo CANCRO EPITELIALE DELL OVAIO:
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More information7. Cytoreductive surgery in endometrial cancer and uterine sarcomas
Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 123-151 ISBN: 978-81-7895-484-4 Editor:
More informationBiological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report
ONCOLOGY LETTERS 9: 1239-1243, 2015 Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report SHIGAO HUANG *, YAZHENG
More information1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian
1. Engel J, Eckel R, Schubert-Fritschle G, et al. Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002;38(18):2435-45.
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationAbstract. Materials and methods
Int J Gynecol Cancer 2006, 16, 490 495 Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures A.-A.K. TENTES, C.G. MIRELIS, S.K. MARKAKIDIS,
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationRecurrent Ovarian Cancer: Spectrum of Imaging Findings
Recurrent Ovarian Cancer Women s Imaging Pictorial Essay Downloaded from www.ajronline.org by 80.243.130.157 on 03/08/18 from IP address 80.243.130.157. Copyright RRS. For personal use only; all rights
More informationCONTRIBUTION. Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma
CONTRIBUTION Outcome of primary cytoreduction surgery for advanced epithelial ovarian carcinoma DAVID B. SEIFER, MD*; ALEXANDER W. KENNEDY, MD; KENNETH D. WEBSTER, MD; SHARON VANDERBRUG MEDENDORP, MPH;
More informationComparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer
DOI 10.1007/s13224-013-0425-z ORIGINAL ARTICLE Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer Sayyah-Melli Manizheh Zonoozi
More informationOutcomes of palliative bowel surgery for malignant bowel obstruction in patients with gynecological malignancy
ONCOLOGY LETTERS 4: 883-888, 2012 Outcomes of palliative bowel surgery for malignant bowel obstruction in patients with gynecological malignancy TOMOKO GOTO, MASASHI TAKANO, TADASHI AOYAMA, MORIKAZU MIYAMOTO,
More informationSurgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer
Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant
More informationNeoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in advanced ovarian carcinoma
Original article Kasr El-aini J. Clin. Oncol. nucl. med. vol. 8, no. 1-2, Jan.-April. 2012:12-17 Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in advanced
More informationIncidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer
Gynecologic Oncology 103 (2006) 871 877 www.elsevier.com/locate/ygyno Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer Eric L. Eisenhauer
More informationEpithelial Ovarian Cancer
Epithelial Ovarian Cancer GYNE/ONC Practice Guideline Dr. Alex Hammond Dr. Ian Kerr Dr. Akira Sugimoto Dr. Stephen Welch Kay Faroni Christine Gawlik Kerri Thornton Approval Date: This guideline is a statement
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More informationOutcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single
More informationBACKGROUND: STUDY DESIGN: RESULTS: CONCLUSIONS: Disclosure Information: Nothing to disclose.
Surgical Procedures and Morbidities of Diaphragmatic Surgery in Patients Undergoing Initial or Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Sebastien Gouy, MD, Elisabeth Chereau, MD, Ana
More informationAnshuma Bansal 1 Bhavana Rai
DOI 10.1007/s13224-016-0926-7 ORIGINAL ARTICLE Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional
More informationSignificance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma
ORIGINAL STUDY Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma Jeong-Yeol Park, MD, PhD, Dae-Yeon Kim, MD, PhD, Dae-Shik Suh, MD, PhD, Jong-Hyeok Kim, MD, PhD, Yong-Man
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationClinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer
Qin et al. Journal of Ovarian Research (2018) 11:49 https://doi.org/10.1186/s13048-018-0422-z RESEARCH Open Access Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment
More informationA Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer
The Oncologist Gynecologic Oncology A Prospective Outcomes Analysis of Palliative Procedures Performed for Malignant Intestinal Obstruction Due to Recurrent Ovarian Cancer DENNIS S. CHI, a REBECCA PHAËTON,
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationIntraperitoneal chemotherapy: where are we going? A. Gadducci Pisa
Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationDelaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant chemotherapy and interval cytoreduction
Gynecologic Oncology 104 (2007) 480 490 www.elsevier.com/locate/ygyno Review Delaying the primary surgical effort for advanced ovarian cancer: A systematic review of neoadjuvant and interval cytoreduction
More information2007 Cancer Committee
2007 Cancer Committee Ovarian Cancer Study Stage III & IV Albert Bonebrake, MD Rosie Netzer, RHIT, CTR Joanne Schahuber, R.T.(R)(T)(M)(QM) Table of Contents Table of Contents... 1 Ovarian Cancer Facts:...
More informationComparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer
J Gynecol Oncol. 2016 Sep;27(5):e46 pissn 2005-0380 eissn 2005-0399 Original Article Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial
More informationRelapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following
More informationImprovements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture
Original Article J Gynecol Oncol Vol. 24, No. 4:352-358 pissn 2005-0380 eissn 2005-0399 Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor
More informationPROGNOSTIC VALUE OF SERUM CA-125 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER FOLLOWED BY COMPLETE REMISSION AFTER ADJUVANT CHEMOTHERAPY
ORIGINAL ARTICLE Obstet Gynecol Sci 2013;56(1):29-35 http://dx.doi.org/10.5468/ogs.2013.56.1.29 pissn 2287-8572 eissn 2287-8580 PROGNOSTIC VALUE OF SERUM CA-125 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN
More informationCA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers
CA-125 Change After Chemotherapy in Prediction of Treatment Outcome Among Advanced Mucinous and Clear Cell Epithelial Ovarian Cancers A Gynecologic Oncology Group Study Chunqiao Tian, MS 1, Maurie Markman,
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationHE4 Human Epididymal Protein 4 A novel oncological biomarker improving ovarian cancer care
HE4 Human Epididymal Protein 4 A novel oncological biomarker improving ovarian cancer care Ovarian cancer Worldwide, ovarian cancer is the second leading cancer in women and the fourth common cause of
More informationThe Itracacies of Staging Patients with Suspected Lung Cancer
The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung
More informationPrognostic significance of supradiaphragmatic lymph node metastasis detected by 18 F-FDG PET/CT in advanced epithelial ovarian cancer
Lee et al. BMC Cancer (2018) 18:1165 https://doi.org/10.1186/s12885-018-5067-1 RESEARCH ARTICLE Open Access Prognostic significance of supradiaphragmatic lymph node metastasis detected by 18 F-FDG PET/CT
More informationNAACCR Webinar Series 1 Q&A. Fabulous Prizes. Collecting Cancer Data: Ovary 11/3/2011. Collecting Cancer Data: Ovary
NAACCR 2011 2012 Webinar Series Collecting Cancer Data: Ovary Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching this webinar
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationIn 2017, an estimated 22,240 women will
OVARIAN CANCER Ovarian cancer remains the most deadly gynecologic malignancy in the United States. What are the practice implications of recent research results on screening, neoadjuvant chemotherapy,
More informationHIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies
HIPEC Controversies in the Indications and Application of Regional Chemotherapy for Peritoneal Surface Malignancies Crescent City Cancer Update: GI and HPB Saturday September 24, 2016 George M. Fuhrman,
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationAnnual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
bs_bs_banner doi:10.1111/jog.12596 J. Obstet. Gynaecol. Res. Vol. 41, No. 2: 167 177, February 2015 Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationAnnual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013
bs_bs_banner doi:10.1111/jog.12360 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 338 348, February 2014 Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013 Daisuke
More informationNewton Wellesley Hospital 2013
Newton Wellesley Hospital 20 Standard 4.6 Assessment and Evaluation of Treatment Planning Endometrial Cancer Each year a physician member of the cancer committee conducts a study to ensure that diagnostic
More informationHow to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens
How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens Wenxin Zheng, M.D. Professor of Pathology and Gynecology University of Arizona zhengw@email.arizona.edu http://www.zheng.gynpath.medicine.arizona.edu/index.html
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 24 AUGUST 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study William E. Winter
More informationNeoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer
Original Article Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer Deo SVS, Goyal Hemant, Shukla NK, Raina V*, Kumar Lalit*, Srinivas G Departments of Surgical
More informationPROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC
PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy
More informationGENERAL DATA. Sex : female Age : 40 years old Marriage status : married
GENERAL DATA Sex : female Age : 40 years old Marriage status : married CHIEF COMPLAINT Bilateral ovarian tumors discovered by sonography accidentally PRESENT ILLNESS 2003-06-26 :bilateral ovarian tumors
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationCytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium
Jpn J Clin Oncol 2003;33(12)636 641 Cytological Features of Cervical Smears in Serous Adenocarcinoma of the Endometrium Yukiharu Todo, Shinichirou Minobe, Kazuhira Okamoto, Mahito Takeda, Yasuhiko Ebina,
More informationHepatic Resection is Safe for Metachronous Hepatic Metastases from Ovarian Cancer
182 Cancer Biol Niu Med et al. 2012; Hepatic 9: 182-187 Resection doi: for 10.7497/j.issn.2095-3941.2012.03.005 Ovarian Cancer Liver Metastases Original Article Hepatic Resection is Safe for Metachronous
More informationNormal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases A Case Report and Literature Review
doi:10.21873/invivo.11250 Normal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases A Case Report and Literature Review NICOLAE BACALBASA 1, IRINA BALESCU 2, CRISTIAN BALALAU
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationClinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122
Ovarian cancer: recognition and initial management Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationRadical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study
Ren et al. BMC Cancer (2015) 15:583 DOI 10.1186/s12885-015-1525-1 RESEARCH ARTICLE Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational
More informationCancer: recent advances and implications for underwriting
Cancer: recent advances and implications for underwriting Robert Rubens Select 74 Bristol 25 February 2010 Agenda Epidemiology - changing mortality Evidence-base for underwriting breast cancer ovarian
More informationEligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment
Bevacizumab in combination with Paclitaxel and Carboplatin - Frontline Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (This form must be completed before the first
More informationH&E, IHC anti- Cytokeratin
Cat No: OVC2281 - Ovary cancer tissue array Lot# Cores Size Cut Format QA/QC OVC228101 228 1.1mm 4um 12X19 H&E, IHC anti- Cytokeratin Recommended applications: For Research use only. RNA or protein ovary
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationSecondary Surgical Cytoreduction for Advanced Ovarian Carcinoma
original article Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma Peter G. Rose, M.D., Stacy Nerenstone, M.D., Mark F. Brady, Ph.D., Daniel Clarke-Pearson, M.D., George Olt, M.D., Stephen
More informationNew Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationEndometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
More informationOvarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
More informationAscites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer
Xu et al. Journal of Ovarian Research (2016) 9:85 DOI 10.1186/s13048-016-0294-z RESEARCH Open Access Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage
More informationCervical Cancer: 2018 FIGO Staging
Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford
More informationCase Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue
Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized
More information